세계의 커버드 스텐트 시장(2023-2030년)

Overview

Covered stent is a type of vascular stent with a fabric coating that creates a contained tube but is expandable like a bare metal stent. Covered stents are used in endovascular surgical procedures such as endovascular aneurysm repair. Covered stents are composed of fabric or graft material, such as polytetrafluoroethylene (PTFE), covering a metal stent. They have various clinical applications in peripheral arterial disease management.

Applications include treatment of atherosclerotic disease, sealing iatrogenic vessel perforations or ruptures, exclusion of aneurysms and pseudoaneurysms, treatment of arteriovenous fistulae, and management of failing dialysis grafts. Covered stents are used during congenital cardiac interventions to treat stenotic or injured vessels or to exclude unwanted vascular connections.

Covered stents were also utilised in thrombus-laden lesions in native coronary arteries. Covered stents offer an effective bail-out strategy in vessel perforations, are an alternative to surgery for the exclusion of coronary aneurysms, and have a potential role in the treatment of friable embolisation-prone plaques.

Market Dynamics: Drivers and Restraints

Rise in the prevalence of coronary artery diseases

Covered stents have been mainly used for the treatment of potentially life-threatening coronary artery perforation and coronary artery aneurysms. Prior studies suggest that the use of covered stents improves event-free survival, enabling a life-threatening situation to be managed without emergency surgery and with significantly reduced rates of mortality, cardiac tamponade, and major adverse cardiac events

Coronary artery disease is caused by plaque buildup in the wall of the arteries that supply blood to the heart (called coronary arteries). Plaque is made up of cholesterol deposits. Plaque buildup causes the inside of the arteries to narrow over time. This process is called atherosclerosis

For instance, according to the Centers for Disease Control and Prevention updated factsheet 2023, coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021. About 1 in 20 adults age 20 and older have CAD (about 5%).2 In 2021, about 2 in 10 deaths from CAD happen in adults less than 65 years old.

Furthermore, technological advancements in covered stents, the rise in the prevalence of the geriatric population, the increase in the prevalence of coronary artery diseases and improvement in patient outcomes with stenting. Advancements in drug-eluting stent (DES) technologies have consisted of continually refining existing platforms to improve stent delivery and develop more biocompatible drug polymers.

Market Dynamics: Restraint

The most common failure mechanisms of covered stents are failure of delivery, stent dislodgement, and failure to seal the perforation. Failure of delivery was more common with Graftmaster, while stent dislodgement was more common with PK Papyrus. Further improvements in covered stent design are needed to optimize deliverability and minimize the risk of complications.

Also, the high cost associated with these specialized medical devices. Covered stents are often more expensive than traditional stents, which can limit their adoption, particularly in regions with constrained healthcare budgets. Moreover, the limited availability of skilled interventional cardiologists proficient in deploying covered stents further hampers the overall market.

Segment Analysis

The global covered stents is segmented based on product type, material type, application, end-user and region.

The balloon expandable vascular-covered stent segment accounted for approximately 41.2% of the market share

The balloon expandable vascular covered stent from the product type segment accounted for 41.2% and it is expected to be dominated during the forecast period. Balloon Expandable Vascular Covered Stent is indicated for the treatment of atherosclerotic lesions in common and external iliac arteries. Balloon-expandable covered stents are medical devices used in interventional cardiology and vascular surgery to treat vascular conditions like aneurysms and stenoses. They consist of a metal framework covered with a synthetic fabric or polymer material.

Moreover, in September 2022, Medtronic set forth that it recently received a CE mark for its Radiant balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the Endurant II/Iis stent graft system. The Endurant II/Iis stent graft and Radiant covered stent offer a standardized, fully on-label, off-the-shelf solution for short-neck, juxtarenal abdominal aortic aneurysms (AAA). This enables safe and effective endovascular repair in both urgent and elective juxtarenal AAA cases, with a proven device combination, backed by clinical outcomes.

Geographical Analysis

Europe accounted for approximately 28.4% of the market share in 2022

Europe is estimated to hold about 28.4% of the total market share throughout the forecast period, owing to the novel product launches, technological advancements, collaboration with the key players, approvals and others that will drive this region further during the forecast period.

For instance, in September 2022, Getinge joined forces with Medtronic to launch a Radiant stent for ChEVAR procedures in Europe which received a CE mark.

Radiant, is the first covered stent which is designed for use in chimney endovascular aneurysm repair (ChEVAR) with the Endurant II/Iis stent graft system. It maintains perfusion to renal arteries when used in combination with the stent graft

Furthermore, in May 2021, iVascular has recently received CE mark approval for its BX-covered stent iCover. Balloon-expanding (BX) covered stents are commonly used for treating arteriosclerotic lesions in renal and iliac arteries and for the treatment of aneurysms and ruptures.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global covered stents market importantly, new studies and registers shows that the percentage of stent thrombosis increased during the COVID-19 pandemic, even up to 8.1-21%, however, the study populations were relatively low. COVID-19, due to direct and indirect effects, creates a significant burden on the cardiovascular system.

Due to the high infection rate and lockdown regulations brought on by the COVID-19 pandemic, surgical procedures have been affected. Additionally, patients with cardiovascular diseases have experienced delays in diagnosis and treatment as a result of fewer people visiting hospitals and diagnostic facilities, which has affected the covered stent market.

Competitive Landscape

The major global players in the covered stents market include: Becton, Dickinson and Company, B. Braun Interventional Systems Inc., Getinge, Insrtumed Surgical, Inc., Boston Scientific Corporation, Biotronik, Mermaid Medical, Gore Medical, Getz Healthcare, iVascular S.L.U and among others.

Why Purchase the Report?

• To visualize the global covered stents market segmentation-based product type, material type, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of covered stents market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global covered stents market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Material Type
• 3.3. Snippet by Application
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Driver
    • 4.1.1.1. Rise in the prevalence of coronary artery diseases
    • 4.1.1.2. Rise in the technology advancements
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects of Toxoid Vaccine
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Balloon Expandable Covered Stents *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Bare Metal Covered Stents
• 7.4. Drug-Eluting Covered Stents
• 7.5. Bioabsorbable Covered Stents

8. By Material Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 8.1.2. Market Attractiveness Index, By Material Type
• 8.2. ePTFE (Expanded Polytetrafluoroethylene) Covered Stents*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Polyurethane
• 8.4. Polyester Covered Stents

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Peripheral Vascular Aneurysms *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Coarctation of the Aorta
• 9.4. Atherosclerotic Diseases
• 9.5. Coronary Artery Perforations

10. By End User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.1.2. Market Attractiveness Index, By End User
• 10.2. Hospitals *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Ambulatory Surgical Centers (ASCs)

11. Cardiac Specialty Clinics

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.7.1. U.S.
    • 12.2.7.2. Canada
    • 12.2.7.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.7.1. Germany
    • 12.3.7.2. UK
    • 12.3.7.3. France
    • 12.3.7.4. Italy
    • 12.3.7.5. Spain
    • 12.3.7.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Market Positioning/Share Analysis
• 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

• 14.1. Becton, Dickinson and Company
  • 14.1.1. Company Overview
  • 14.1.2. Product Type Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. B. Braun Interventional Systems Inc
• 14.3. Getinge
• 14.4. Insrtumed Surgical, Inc
• 14.5. Boston Scientific Corporation
• 14.6. Biotronik
• 14.7. Mermaid Medical
• 14.8. Gore Medical
• 14.9. Getz Healthcare
• 14.10. avascular S.L.U

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us